Sandbox:Hannan: Difference between revisions
Jump to navigation
Jump to search
Hannan Javed (talk | contribs) No edit summary |
Hannan Javed (talk | contribs) No edit summary |
||
Line 5: | Line 5: | ||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ | ||
!Other myeloid neoplasm and acute leukemia | ! rowspan="2" |Other myeloid neoplasm and acute leukemia | ||
! | ! colspan="2" |Clinical manifestations | ||
! | ! colspan="4" |Diagnosis | ||
! | ! rowspan="2" |Other features | ||
|- | |||
!Symptoms | |||
!Physical examination | |||
!Lab findings | |||
!Bone marrow biopsy | |||
!Gold standard | |||
!Other investigations | |||
|- | |- | ||
|Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of | |Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of | ||
Line 16: | Line 23: | ||
* Myeloid/lymphoid neoplasms with FGFR1 rearrangement | * Myeloid/lymphoid neoplasms with FGFR1 rearrangement | ||
* Provisional entity: Myeloid/lymphoid neoplasms with PCM1-JAK | * Provisional entity: Myeloid/lymphoid neoplasms with PCM1-JAK | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 26: | Line 37: | ||
* MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) | * MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) | ||
* MDS/MPN, unclassifiable | * MDS/MPN, unclassifiable | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 41: | Line 56: | ||
* Provisional entity: Refractory cytopenia of childhood | * Provisional entity: Refractory cytopenia of childhood | ||
* Myeloid neoplasms with germ line predisposition | * Myeloid neoplasms with germ line predisposition | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 74: | Line 93: | ||
# Transient abnormal myelopoiesis (TAM) | # Transient abnormal myelopoiesis (TAM) | ||
# Myeloid leukemia associated with Down syndrome | # Myeloid leukemia associated with Down syndrome | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 79: | Line 102: | ||
|- | |- | ||
|Blastic plasmacytoid dendritic cell neoplasm | |Blastic plasmacytoid dendritic cell neoplasm | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 89: | Line 116: | ||
* MPAL, B/myeloid, NOS | * MPAL, B/myeloid, NOS | ||
* MPAL, T/myeloid, NO | * MPAL, T/myeloid, NO | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 105: | Line 136: | ||
* Provisional entity: B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like | * Provisional entity: B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like | ||
* Provisional entity: B-lymphoblastic leukemia/lymphoma with iAMP | * Provisional entity: B-lymphoblastic leukemia/lymphoma with iAMP | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 112: | Line 147: | ||
* Provisional entity: Early T-cell precursor lymphoblastic leukemia | * Provisional entity: Early T-cell precursor lymphoblastic leukemia | ||
* Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymph | * Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymph | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 119: | Line 158: | ||
! colspan="2" |Clinical manifestations | ! colspan="2" |Clinical manifestations | ||
! colspan="4" |Diagnosis | ! colspan="4" |Diagnosis | ||
!Other Features | ! rowspan="2" |Other Features | ||
|- | |- | ||
!Symptoms | !Symptoms | ||
Line 126: | Line 165: | ||
!Bone Marrow Biopsy | !Bone Marrow Biopsy | ||
!Gold Standard | !Gold Standard | ||
! | !Other investigations | ||
|- | |- | ||
|Chronic myeloid leukemia | |Chronic myeloid leukemia |
Revision as of 12:39, 15 January 2019
Other myeloid neoplasm and acute leukemia | Clinical manifestations | Diagnosis | Other features | ||||
---|---|---|---|---|---|---|---|
Symptoms | Physical examination | Lab findings | Bone marrow biopsy | Gold standard | Other investigations | ||
Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of
PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2
|
|||||||
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
|
|||||||
Myelodysplastic syndromes (MDS)
|
|||||||
Acute myeloid leukemia (AML) and related neoplasms
|
|||||||
Blastic plasmacytoid dendritic cell neoplasm | |||||||
Acute leukemias of ambiguous lineage
|
|||||||
B-lymphoblastic leukemia/lymphoma
|
|||||||
T-lymphoblastic leukemia/lymphoma
|
(CML), BCR-ABL1+
- prefibrotic/early stage
- overt fibrotic stage